Effect of fish oil as an adjunct therapy to metformin on vascular and cardiac health in women with polyendocrine metabolic ovarian syndrome: protocol for a randomised, placebo-controlled clinical trial Authors: Beate Sydora, Mahua Ghosh, Sarah Chambers, Anne Haase, Margie Davenport, Christian Beaulieu, Richard Thompson, Jonathan Windram, Harald Becher, Paolo Raggi, Donna Vine Published: 2026 ABSTRACT AbstractIntroductionPolyendocrine metabolic ovarian syndrome (PMOS) (formerly known as polycystic ovary syndrome) is a metabolic-endocrine disorder that affects 8–13% of women globally and is associated with increased cardiovascular disease (CVD) across the lifespan. CVD develops in young women due to risk factors such as atherogenic dyslipidaemia, insulin resistance and elevated body weight. High-risk overweight-obese young women with PMOS often present with subclinical CVD including atherosclerotic CVD and cardiac hypertrophy. Metformin is prescribed as standard of care to treat insulin resistance and prevent development of diabetes; however, current guidelines and treatments inadequately address atherogenic dyslipidaemia and premature subclinical CVD, particularly in young women with PMOS. The aim of this trial is to evaluate the efficacy of fish oil as an adjunct therapy to standard-of-care metformin treatment in reducing plasma triglycerides and apoB-lipoproteins, thereby preventing the progression of premature atherosclerosis and cardiac remodelling-dysfunction in young high-risk women with PMOS.Methods and analysisWe will conduct a randomised, double-blind, placebo-controlled, parallel study with two intervention arms following a superiority framework. The study is being carried out at the University of Alberta Hospital and laboratories from November 2025 to July 2028. Participants will self-identify and/or be recruited from PMOS social media websites, flyers and clinics in Edmonton and the Greater Edmonton Area. Included will be women who have overweight or obesity (body mass index >25 kg/m2), are aged 25–45 years and have a PMOS diagnosis and elevated fasting plasma triglyceride or apoB levels. The participants (n=146) will be allocated (1:1) to the experimental group receiving fish oil (5.96 g/day) or the control group receiving a placebo over a 12-month period; participants in both groups will receive standard-of-care metformin (1500 mg/day). Primary outcome measures will be carotid intimal medial thickness, carotid plaque height and left ventricular global longitudinal strain. Secondary outcomes will include blood lipids, apoB-lipoproteins, hormones and glucose-insulin. Methodologies will include standard biochemical laboratory tests, MRI and ultrasound/echocardiography. Questionnaires on quality of life and interviews exploring programme satisfaction, adherence and compliance at the beginning and end of the trial will inform future studies and PMOS management.Ethics and disseminationThe study is approved by the University of Alberta Human Research Ethics Board (ethics file ID: Pro00141704). Written informed consent to participate will be obtained from all participants. Trial outcomes will be communicated to the wider public, including trial participants, healthcare professionals managing patients with PMOS and the scientific community involved in PMOS research via infographics to relevant PMOS websites, presentations in community forums and at scientific meetings, and publications in scientific journals.Trial registration numberNCT06424860.Keywords: Cardiovascular Disease, Lipid disorders, Polyendocrine metabolic ovarian syndrome, Cardiac function and atherosclerosis, Fish oil and metformin STRENGTHS AND LIMITATIONS OF THIS STUDY The study will be blinded for both participants and investigators, including personnel involved in conducting tests and laboratory analysis, to avoid bias. The study will be blinded for both participants and investigators, including personnel involved in conducting tests and laboratory analysis, to avoid bias. The study design will be parallel and placebo controlled, following a superiority framework. The study design will be parallel and placebo controlled, following a superiority framework. The study aims to explore participant satisfaction and acceptability of the intervention to help translate to clinical practice implementation and inform a potential larger scale multicentre trial in the future. The study aims to explore participant satisfaction and acceptability of the intervention to help translate to clinical practice implementation and inform a potential larger scale multicentre trial in the future. Study participation is limited to high-risk, overweight-obese individuals with PMOS which reduces translation of findings to other populations or phenotypes of PMOS. Study participation is limited to high-risk, overweight-obese individuals with PMOS which reduces translation of findings to other populations or phenotypes of PMOS. A limitation of this study is that it will not exclude participants using medications such as anti-androgens, diabetes and obesity medications and hormonal contraception which potentially could confound outcomes depending on the formulation and duration of use prior to the study. A limitation of this study is that it will not exclude participants using medications such as anti-androgens, diabetes and obesity medications and hormonal contraception which potentially could confound outcomes depending on the formulation and duration of use prior to the study. Introduction Polyendocrine metabolic ovarian syndrome (PMOS) is a metabolic-endocrine disorder that occurs in 8–13% of young women globally and impacts health and quality of life (QOL) across the lifespan.1–7 PMOS was formerly termed polycystic ovary syndrome (PCOS). The new name better reflects the pathophysiology, endocrine and metabolic dysfunction of the syndrome.8 Our trial was registered with Health Canada clinical trials before the name change on 12 May 2026. The diagnosis of PMOS is based on the presence of two out of three of the following criteria: menstrual irregularity/ovulatory dysfunction, clinical or biochemical hyperandrogenism and polyfollicular ovaries.9 PMOS is a major public health concern marked by increased risk of infertility and comorbidities.3–5 10–13 It is highly associated with the metabolic syndrome: obesity, insulin resistance and dyslipidaemia, predisposing young women to develop type 2 diabetes (T2D), metabolic dysfunction-associated fatty liver disease and cardiovascular disease (CVD).5 14–24 Increased risk of pregnancy-related complications including gestational diabetes, gestational hypertension and pre-eclampsia, in addition to a higher use of assisted reproductive technology in women with PMOS, can further increase the risk of postpartum cardiovascular complications and CVD.12 25–27 Those with PMOS are prone to premature development of atherosclerotic CVD (ACVD), with 70% of patients displaying atherogenic dyslipidaemia, a primary risk factor for ACVD.5 17 28–32 Atherogenic dyslipidaemia is characterised by elevated plasma triglyceride (TG), increased levels of cholesterol and apolipoprotein B (apoB)-containing TG-rich lipoproteins—specifically apoB48 derived from the intestine and apoB100 derived from the liver—as well as reduced levels of high-density lipoprotein-associated cholesterol (HDL-C).33 34 We have evidence to show that high-risk adolescents and young women with overweight-obesity and PMOS have elevated fasting and non-fasting plasma TG, apoB48 and apoB100, predisposing them to exacerbated development of ACVD.32 35–37 The pathology of dyslipidaemia in PMOS is associated with elevated testosterone and insulin levels, and these can upregulate lipid and lipoprotein synthesis in the intestine and liver.37–40 Despite the high prevalence of dyslipidaemia in PMOS, there are limited studies on interventions to target atherogenic dyslipidaemia in young women of reproductive age with PMOS.9 33 41–44 The first-line intervention recommended in patients with PMOS is to target metabolic risk and manage body weight by improving dietary and lifestyle habits.9 However, meta-analyses have shown that patients with PMOS with elevated body weight can be metabolically resistant to dietary-lifestyle interventions, and these can have limited effectiveness to improve dyslipidaemia.45–47 Similarly, while metformin is the standard of care for treating insulin resistance and pre-diabetes in PMOS, it is limited in improving plasma lipids.48–52 Furthermore, lipid-lowering pharmaceutical agents, including statins and anti-obesity/anti-diabetes medications, such as glucagon-like protein-1 receptor agonists, are often contraindicated in women of reproductive age due to adverse side effects, and insufficient pregnancy and long-term safety data.9 33 53–63 Fish oil contains long-chain fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which have well-established efficacy to reduce plasma TG and apoB-lipoproteins in the metabolic syndrome and in those with PMOS.36 64–72 Our preliminary data show that fish oil as an adjunct therapy to metformin (standard of care to prevent and manage diabetes) reduces plasma TG and apoB-lipoproteins in young overweight-obese women with PMOS.36 These findings are clinically relevant in the reduction of atherogenic TG-rich apoB-lipoproteins and their remnants, which are causative in atherosclerosis.73–77 The increased risk in ACVD development in young women with elevated weight and PMOS is also evidenced by carotid intimal medial thickness (cIMT) and carotid plaque.32 78–80 In addition, they display impaired endothelial function, hypertension and cardiac remodelling-dysfunction including left ventricular (LV) hypertrophy and LV global longitudinal strain (GLS).24 30 32 81–86 No studies to date have investigated interventions that target prevention of progression of ACVD, endothelial dysfunction and cardiac remodelling-dysfunction in young high-risk women with PMOS.22 87 It has been proposed that a healthcare focus should be on (a) early CVD screening with research investigating subclinical CVD and risk markers and (b) management of dyslipidaemia and prevention of subclinical CVD progression by exploring effective and safe approaches in young reproductive-aged women.32 43 87 88 There is a need for long-term studies on the assessment of subclinical CVD and the development of risk prediction models for screening and monitoring of progression and preventative measures in ameliorating premature CVD in high-risk women, especially those with overweight-obesity and PMOS.31 88 89 This proposed study addresses a critical gap in evidence-based research by supporting early CVD screening for premature ACVD, endothelial dysfunction and cardiac remodelling-dysfunction as well as evaluating a cost-effective, safe treatment to target atherogenic dyslipidaemia and subclinical CVD risk in young women of reproductive age with PMOS. The findings from this study have the potential to guide therapeutic management and primary prevention of atherogenic dyslipidaemia and premature CVD in high-risk young women with PMOS. Objectives The overall objective of this study is to determine the effectiveness of fish oil as an adjunct therapy to standard-of-care metformin over 1 year in reducing plasma TG and apoB-lipoproteins and in preventing the progression of premature atherosclerosis, endothelial dysfunction and cardiac remodelling-dysfunction in young high-risk women with PMOS. Specific objectives To determine the effect of fish oil as an adjunct therapy to metformin on the progression of cIMT and carotid plaque height over a period of 12 months. To determine the effect of fish oil as an adjunct therapy to metformin on the progression of cIMT and carotid plaque height over a period of 12 months. To determine the effect of fish oil as an adjunct therapy to metformin on the progression of endothelial dysfunction and cardiac remodelling-dysfunction. To determine the effect of fish oil as an adjunct therapy to metformin on the progression of endothelial dysfunction and cardiac remodelling-dysfunction. To determine the association of plasma TG and apoB-lipoproteins and other cardiometabolic risk factors with progression of cIMT and carotid plaque height, endothelial function and cardiac remodelling-function indices following fish oil supplementation with metformin. To determine the association of plasma TG and apoB-lipoproteins and other cardiometabolic risk factors with progression of cIMT and carotid plaque height, endothelial function and cardiac remodelling-function indices following fish oil supplementation with metformin. Additional objectives We will assess adherence, feasibility and acceptability to the trial intervention through analysis of participant dropout, pre and post QOL questionnaires and participant perception of barriers and facilitators to adherence, met expectations and satisfaction using short interviews. Methods and analysis Trial design We will conduct a randomised, double-blind, placebo-controlled, parallel-group study in high-risk young women with PMOS following a superiority framework. The trial protocol (version 13 August 2025) is guided by the reporting checklist for protocols of a clinical trial based on Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines to ensure reliability and transparency in the study’s execution.90 The SPIRIT checklist is appended as online supplemental file 2. Study setting The study will be conducted at locations at University of Alberta, Edmonton, Canada. Assessment and interventions will take place at laboratories and clinics that are approved operational sites and affiliated with the University of Alberta and University Alberta Hospital. Participants will be recruited from the Greater Edmonton Area via advertisement on our PMOS Together social media and other university and community websites; referred from collaborating healthcare professionals, including endocrinologists, family physicians and obstetrician-gynaecologists; and from the Lois Hole Hospital for Women, Women and Children’s Health Research Institute (WCHRI) and the Endocrinology and Metabolism Clinic at the University of Alberta Hospital divisional triage pool following referral by family physicians. Participants may also self-identify and contact the research team in response to advertising posted on PMOS Together social media, women’s health, obstetrics and gynaecology, and endocrinology clinics. Enrolment started on 7 November 2025. Participant eligibility criteria The focus of this study is on high-risk young women with overweight-obesity, aged 25–45 years with a diagnosis of PMOS. Individuals with the following inclusion criteria will be our participants and they represent the most common high-risk cardiometabolic and ACVD risk phenotype.9 Inclusion criteria Diagnosis of PMOS: based on international guidelines.9 Diagnosis of PMOS: based on international guidelines.9 Body mass index (BMI) >25 kg/m2. Body mass index (BMI) >25 kg/m2. Aged 25–45 years. Aged 25–45 years. Use of prescribed metformin (1500 mg/day) as standard of care for the duration of the trial. Use of prescribed metformin (1500 mg/day) as standard of care for the duration of the trial. Elevated fasting plasma TG (>1.7 mM) and/or apoB (>0.8 g/L) following Canadian Cardiovascular Society guidelines.33 Elevated fasting plasma TG (>1.7 mM) and/or apoB (>0.8 g/L) following Canadian Cardiovascular Society guidelines.33 Impaired fasting glucose (glucose 6.1–6.9 mmol/L) or impaired glucose tolerance (2-hour blood glucose, 75 g oral glucose tolerance test (OGTT) (7.8–11 mmol/L)), or pre-diabetes (A1C 6.0–6.4%), diagnosed with T2D (blood glucose ≥7.0 mmol/L or random blood glucose ≥11.1 mmol/L or A1C ≥6.5% or 2-hour blood glucose, 75 g OGTT ≥11.1 mmol/L) following the Diabetes Canada guidelines,91 or insulin (≥120 pmol/L). Impaired fasting glucose (glucose 6.1–6.9 mmol/L) or impaired glucose tolerance (2-hour blood glucose, 75 g oral glucose tolerance test (OGTT) (7.8–11 mmol/L)), or pre-diabetes (A1C 6.0–6.4%), diagnosed with T2D (blood glucose ≥7.0 mmol/L or random blood glucose ≥11.1 mmol/L or A1C ≥6.5% or 2-hour blood glucose, 75 g OGTT ≥11.1 mmol/L) following the Diabetes Canada guidelines,91 or insulin (≥120 pmol/L). We will include participants with an ongoing metformin prescription and those with newly prescribed metformin as standard of care. If not already taking 1500 mg/day, participants will be asked to increase their metformin dose incrementally to achieve the trial dosage of 1500 mg/day (500 mg tablet, three times per day) prior to the first clinic visit. The metformin dosage of 1500 mg/day is typical for standard of care to improve insulin sensitivity in PMOS, but doses of up to 2500 mg/day may be required in participants based on management of blood glucose.9 52 For participants experiencing mild to moderate intolerance, lower doses or divided dosing may be used. We will adjust for the dosage and length of metformin use in post hoc statistical analyses. Exclusion criteria Pregnancy or lactating. Pregnancy or lactating. Unwilling to use an effective method of contraception while participating in the study. Unwilling to use an effective method of contraception while participating in the study. Use of lipid-lowering or anticoagulant drugs. Use of lipid-lowering or anticoagulant drugs. Type 1 diabetes (T1D). Type 1 diabetes (T1D). History of lactic acidosis. History of lactic acidosis. Renal impairment (estimated glomerular filtration rate <60 mL/min). Renal impairment (estimated glomerular filtration rate <60 mL/min). Use of medications and natural health products (NHPs), unless deemed necessary as part of ongoing healthcare and the impact on study findings is deemed minimal. Use of medications and natural health products (NHPs), unless deemed necessary as part of ongoing healthcare and the impact on study findings is deemed minimal. Regular consumption of fish oil before the trial and/or consumption of fish oil/EPA-DHA supplements (other than provided in the trial) during the trial. Participants can be included if they undergo a washout period of 8 weeks for previous fish oil supplementation prior to the start of the trial. Regular consumption of fish oil before the trial and/or consumption of fish oil/EPA-DHA supplements (other than provided in the trial) during the trial. Participants can be included if they undergo a washout period of 8 weeks for previous fish oil supplementation prior to the start of the trial. Known allergy to any of fish oil, vitamin E, vitamin C, sunflower oil, rosemary, glycerin or gelatin. Known allergy to any of fish oil, vitamin E, vitamin C, sunflower oil, rosemary, glycerin or gelatin. Known allergy to any of metformin hydrochloride, colloidal silicon dioxide, hypromellose, povidone, sodium starch glycolate or magnesium stearate. Known allergy to any of metformin hydrochloride, colloidal silicon dioxide, hypromellose, povidone, sodium starch glycolate or magnesium stearate. Severely high TG levels (500 mg/dL or 5.65 mmol/L or higher). Severely high TG levels (500 mg/dL or 5.65 mmol/L or higher). Severe metformin intolerance and unable to increase to the dose required for the study. Severe metformin intolerance and unable to increase to the dose required for the study. Any condition or situation that, in the opinion of the investigators, could compromise patient safety. Any condition or situation that, in the opinion of the investigators, could compromise patient safety. Exclusion criteria will help avoid confounding and misrepresentation of outcome data. Because of the hormonal changes during pregnancy, participants will need to delay pregnancy for the duration of the trial. All participants with possibility of pregnancy will be recommended to use effective medically acceptable barrier methods of contraception such as intrauterine device and barrier methods with spermicide. If patients are already taking a combined hormonal contraceptive at the time of recruitment and do not want to discontinue this contraception method, they will need to continue the same oral contraceptive throughout the trial. We will adjust for hormonal contraceptive use in post hoc statistical data analyses. Randomisation and blinding On consent and enrolment, eligible participants who are using metformin as standard of care will be randomly allocated to one of two intervention arms in a 1:1 ratio: the experimental group will receive fish oil, the control group will receive a placebo. Placebo capsules are designed to mimic and be outwardly indistinguishable from the fish oil supplements. For randomisation, we will use permuted blocks of randomly varied sizes based on allocation tables that have been generated for this study. Only the study coordinator will be unblinded to the allocation and will provide the experimental capsules (fish oil or placebo). Stratification variables include age, BMI and hormonal contraception use. Participants will be identified by a study ID number generated during randomisation, and only the designated study coordinator knows which ID numbers correspond to which treatment arm. Researchers—including personnel involved in conducting tests and laboratory analysis—and participants will be blinded to the assigned intervention. Participants reporting on treatment side effects will be unblinded and referred to the qualified investigator (QI) in our team for advice on continuing/modifying intervention requirements. If side effects are severe, participants may have to be withdrawn from the study, and intention-to-treat analyses will be applied.92 An audit trail including the assigned study ID number, treatment allocation and date and time of the transaction will be maintained in a secure Research Electronic Data Capture (REDCap) database.93 Intervention Fish oil is provided as soft capsules at a concentration of 1.49 g, including 750 mg EPA and 250 mg DHA (Nature’s Way Brands, Green Bay, Wisconsin). Study participants in the experimental group will be asked to take two capsules orally two times per day over the entire intervention period for a daily total of 5.96 g of fish oil (3000 mg EPA+1000 mg DHA). The dosage of 4000 mg/day EPA and DHA in fish oil is based on previous effective doses to lower plasma TG in the metabolic syndrome, T2D and our data to reduce plasma TG and apoB48 lipoproteins in PMOS.36 66 70–72 94 95 Fish oil supplement is a commonly used NHP and its safety is well established96; no interactions have been reported between standard-of-care metformin and fish oil.36 The participants in the control group will be provided with a placebo composed of soft gel capsules with olive oil (Aspire Pharmaceuticals, Somerset, New Jersey) to take orally two times per day. Study timeline Participation in the trial will be for 12 months and includes prescreening and five clinic visits in 3-month intervals. The treatment plan, timeline and assessments are outlined in table 1. Table 1Timeline and treatment planTimepointsStudy periodEnrolmentClinic visit 1Clinic visit 2Clinic visit 3Clinic visit 4Clinic visit 5Close-outPre-clinic assessmentsStartAt 3 monthsAt 6 monthsAt 9 monthsAt 12 months12–13 monthsEnrolment Eligibility screeningx Informed consentx AllocationxInterventions Intervention supply*xxxxAssessments Age and PMOS diagnosisx Participant surveys†x Laboratory requisition‡xxx Weight/height/BMIxxxx Concomitant medicationsxxxxxx 3-day food record§xxx 12-hour fasting serum testxxx Hip/waist circumferencexxx Body compositionxx High-fat meal testxx Echocardiography, tonometry, MRI¶xx QOL questionnairesxx Acceptability interview**xx Adverse event assessmentxxxxx Intervention compliancexxxxx DHA/EPA in erythrocytes††xx*Intervention includes allocation to either the fish oil or the placebo arm and a 3-month supply of the allocated capsules.†Participants will complete a demographic survey at or before clinic visit 1.‡Laboratory requisition will include lipid panel, apoB, insulin, glucose and hormones, including hCG for pregnancy testing.§A 24-hour food record on three consecutive days will be completed by participants about 1 week before their clinic appointment. It will be reviewed and discussed with a Registered Dietitian.¶Echocardiography, tonometry and MRI will assess ACVD, PWV and cardiac function.**The interview includes questions on expectations at the beginning of the trial and questions on satisfactions at the end of the trial.††DHA and EPA enrichment in erythrocyte phospholipids will be measured via gas chromatography.ACVD, atherosclerotic cardiovascular disease; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; hCG, human chorionic gonadotropin; PMOS, polyendocrine metabolic ovarian syndrome; PWV, pulse wave velocity; QOL, quality of life. Timeline and treatment plan Intervention includes allocation to either the fish oil or the placebo arm and a 3-month supply of the allocated capsules. Participants will complete a demographic survey at or before clinic visit 1. Laboratory requisition will include lipid panel, apoB, insulin, glucose and hormones, including hCG for pregnancy testing. A 24-hour food record on three consecutive days will be completed by participants about 1 week before their clinic appointment. It will be reviewed and discussed with a Registered Dietitian. Echocardiography, tonometry and MRI will assess ACVD, PWV and cardiac function. The interview includes questions on expectations at the beginning of the trial and questions on satisfactions at the end of the trial. DHA and EPA enrichment in erythrocyte phospholipids will be measured via gas chromatography. ACVD, atherosclerotic cardiovascular disease; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; hCG, human chorionic gonadotropin; PMOS, polyendocrine metabolic ovarian syndrome; PWV, pulse wave velocity; QOL, quality of life. There will be monthly or as required in-person or virtual follow-up visits after the start of the intervention with a clinical coordinator and/or Registered Dietitian for dietary-lifestyle counselling and monitoring of adherence. As this is a parallel study design, there will be no washout period during the length of the trial. Prescreening Recruited and consented participants will be prescreened to verify a diagnosis of PMOS and will complete a laboratory requisition to ensure inclusion criteria are met. A serum or urine pregnancy test for human chorionic gonadotropin (hCG) will be performed if deemed necessary at prescreening. Body weight and height (to determine BMI), as well as waist and hip circumference, will be measured. Participants found eligible will be randomised and scheduled for five in-person clinical visits over the year. Clinic visits Clinic visit 1 marks the start of the intervention. Participants will be asked to complete a 24-hour food record on three consecutive days before clinic visit 1. They will be required to fast for 12 hours before their appointment to assess fasting blood lipids, hormones and glucose-insulin. Subsequently, they will be given a high-fat meal challenge test to assess non-fasting response in plasma lipids and apoB-lipoproteins. Participants will have their body composition measured and undergo assessments for ACVD, including pulse wave velocity (PWV) and cardiac morphology and function. During the clinic visit they will be asked to complete QOL questionnaires and answer a few questions about their study expectations and possible challenges of participating in this trial. Participants will be provided with a 3-month supply of the assigned intervention (fish oil or placebo) to start immediately after the visit. Clinic visits 2–5 follow in 3-month intervals at 3, 6, 9 and 12 months to assess adverse events and changes in concomitant and new medications or NHPs. After each clinic visit, participants will receive a new supply of their assigned intervention. Participants will repeat the 24-hour food records prior to clinic visits 3 and 5. These records will be reviewed during consultations with a Registered Dietitian, who will provide dietary and lifestyle counselling at the start and throughout the study to ensure participants follow Health Canada’s Eat Well Live Well guidelines, and provincial and international recommendations for PMOS management.9 97–99 The food record will contain portions and weight of portions as applicable. The goal is for the participants to have consistent dietary intake and lifestyle habits throughout the study, and this will be monitored and supported by the dietitian to ensure adherence to dietary guidelines and the intervention. A 12-hour fasting blood sample will be taken at clinic visits 3 and 5 to track fasting lipids through the study. At clinic visit 5, the final visit at 12 months post start of the intervention, participants will undergo the same tests as at clinic visit 1 (table 1). Outcomes Primary outcomes Primary outcome measures will be the change in cIMT, carotid plaque height and LV-GLS following a 12-month metformin plus fish oil treatment. We will use high-resolution two-dimensional (2D) and 3D-ultrasound imaging to assess cIMT and carotid plaque height at baseline clinic visit 1 and at the end of the intervention at clinic visit 5 (12-month assessment). Progression of cIMT and carotid plaque height will be estimated assuming a linear trend with time and will be expressed as percent change, as previously described.100–102 The percent change in PWV and LV-GLS will also be assessed to determine progression of endothelial dysfunction and cardiac remodelling-dysfunction indices. Measurements at clinic visit 1 and clinic visit 5 will include tonometry for PWV, high-resolution 2D echocardiography and MRI to assess outcomes including LV posterior wall thickness and LV ejection fraction (LVEF), as well as 3D speckle tracking echocardiography to assess LV-GLS, as previously described.32 Secondary outcomes Secondary outcome measures will include changes in blood lipids (TG, low-density lipoprotein-associated cholesterol (LDL-C), HDL-C, non-HDL-C (mmol/L)), apoB-lipoproteins (apob48 and apoB100 (mg/L)), remnant cholesterol (remnant-C; mmol/L), testosterone (nmol/L), insulin (pmol/L) and glucose (nmol/L) from baseline at clinic visit 1 compared with clinic visit 5 at the end of the intervention (12-month assessment). Linear regression analyses will be used to determine the association of the outcomes of progression of cIMT and carotid plaque height, PWV and cardiac remodelling-dysfunction indices with plasma TG and apoB-lipoprotein levels, hormones and cardiometabolic risk factors. Additional outcomes Adherence, feasibility and acceptability to the trial intervention will be assessed through analysis of participant dropout, QOL questionnaires and participant interviews conducted pre-intervention and at 12 months post-intervention start. Data collection and management Demographic and health-related data For eligibility screening and enrolment, we will collect data on participant PMOS-related diagnostic information and medical disease history, such as T1D, T2D, hypertension, metabolic syndrome, CVD and known allergies. We will also check patient healthcare records for information on their current medications and verification of medical history and other relevant biochemical parameters. Biochemical laboratory tests At the screening stage, the following biochemical parameters will be measured: androstenedione (AND), dehydroepiandrosterone sulfate (DHEAS), free and total testosterone, serum hormone binding globulin (SHBG), TG, LDL-C and total cholesterol, non-HDL-C, HDL-C, remnant-C, total apoB, glucose, insulin and haemoglobin A1C. The high-fat meal test has been described in detail previously.35 36 Briefly, a catheter will be inserted into the cubital fossa vein, and a fasting blood sample will be drawn, followed by the consumption of a high-fat milkshake. Blood samples (2 mL each) will then be collected at 2, 4, 6 and 8 hours after drinking the milkshake to assess non-fasting lipid response. Serum hormones and lipids will be measured using Alberta Precision Laboratory protocols, and fasting and non-fasting plasma apoB48 and apoB100-lipoproteins will be quantitated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) western blot methods.35 36 Body anthropometry Participant height, weight, waist circumference and hip circumference will be measured; BMI will be calculated from height and weight (kg/m2). Participant’s body composition will be measured via air displacement plethysmography using Bod Pod and via MRI, as previously described.35 36 103 Data on body mass and volume will be collected and will be used to determine the percentage of fat-free lean muscle and fat mass.35 36 MRI will provide detailed data on body fat distribution (subcutaneous, visceral, hepatic, intermuscular, skeletal muscle) and will be acquired using 2.89T Siemens scanner (Magnetom Prisma, Siemens Healthineers).35 36 103 Cardiovascular data Data for cIMT, carotid plaque height, PWV and cardiac morphology and function will be collected by an experienced vascular technologist using ultrasound/echocardiography methodology, as previously described.32 The arterial blood pressure will be measured by standard manual plethysmography at the brachial artery.32 Central and peripheral PWV (arterial stiffness) will be estimated with tonometry (Complior, Alam Medical, Saint Quentin Fallavier, France), with sensors placed at the carotid-femoral and carotid-radial arterial pulse sites. The distance between measuring sites is divided by the time difference between the upslopes of the pulse waves at each measuring site, and arterial stiffness is expressed as PWV and calculated as the average of at least 10 consecutive beats over a respiratory cycle.104 105 2D high-frequency vascular ultrasound will be used to measure cIMT (L12-3 linear-array probe, frequency 3–12 MHz, axial resolution 0.8 mm; Epiq 7; Philips, Netherlands) on the distal 1 cm of the far wall of the common carotid and is defined as the distance between lumen-intima and media-adventitia interfaces. Mean cIMT values for both right and left common carotid arteries will be calculated using three separate measures for each side to reduce variability and error. The presence or absence of carotid plaque will be determined, and carotid plaque height (mm) will be measured distal to the carotid bulb (Philips Epiq US–Q-lab). Total plaque volume will be calculated semiautomatically by summing the area squares and multiplying by the number of slices in Q-lab.32 106 107 Progression of cIMT and carotid plaque height will be calculated as millimetres per year and percent change per year. Cardiac morphology and function will be determined as previously described using conventional 2D echocardiography to assess LVEF, LV mass, interventricular septum thickness, end-diastolic volume, end-systolic volume and E/A ratio, as well as using our established highly sensitive methods of 2D speckle tracking echocardiography for assessment of LV-GLS.32 108 109 Non-contrast echocardiographic images will be obtained using Epiq C7 scanner (Philips), and LV volume and LVEF analysis is performed offline using semiautomated tracing of end-systolic and end-diastolic endocardial borders from apical two-chamber and four-chamber images; results are obtained using Simpson’s biplane method. Echocardiographic recordings will be analysed using Q-lab (Philips) to measure GLS. Systolic LV-GLS (%) will be obtained by averaging the segmental strain curves at maximum instantaneous peak.32 109 110 In addition, standard ECG-gated MRI sequences will be used to assess cardiac structure and function and native (non-contrast) myocardial T1 and T2 values.94 95 Ventricular volumes, mass, ejection fraction, GLS and myocardial T1 and T2 will be measured using commercially available software (cvi42, version 5.13, Circle, Calgary, Canada).111 112 QOL and programme satisfaction PMOS-related QOL and health-related QOL will be assessed in self-reported, validated questionnaires: the Polycystic Ovary Syndrome-related Quality of Life (PCOSQOL) questionnaire113 and the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) questionnaire,114 115 respectively. To evaluate programme satisfaction, patients will be asked to participate in a small interview at clinic visit 1, including questions on programme expectations and anticipated barriers and facilitators. A similar interview will be conducted for participants at the end of the trial after clinic visit 5, including questions on trial satisfaction and encountered challenges. Adherence and compliance At clinic visits, participants will receive a checklist to record daily intake of the provided capsules. They will be able to report on side effects during their follow-up visits or anytime during the trial. While we do not expect any adverse effects from fish oil in our trial population, we will monitor side effects using a check sheet monitoring form. To confirm compliance, DHA/EPA enrichment in erythrocyte phospholipids will be measured via gas chromatography at the end of the intervention.36 Participants will be considered dropouts if they ask to be withdrawn from the trial, if they have to be removed from the trial due to changes in the eligibility criteria or if they are lost to the trial by not showing up to clinic visits despite reminders sent by email, text or phone. Data management All data collected from patient surveys, patient health records and required tests will be collated and managed in a REDCap database, specifically created for this trial.93 A study coordinator will check data for accuracy, collection completeness, potential duplicate entrances and discontinuation due to study dropout. Statistics Sample size and power calculations With the parallel design, the total number of participants required is n=146, or n=73 in each treatment arm allowing for a 15% dropout or non-compliance (see below) to achieve 80% power to detect a significant (p<0.05, two sided) reduction in the primary outcome of progression of cIMT, carotid plaque height and LV-GLS following treatment with fish oil as an adjunct to standard-of-care metformin compared with metformin alone (with placebo). The effect size (Cohen’s d) and meaningfulness of the difference between the groups were calculated using data from our pilot study and PMOS literature.32 36 116 The effect size was estimated to be moderate at 0.5 for the effectiveness of fish oil as an adjunct to metformin compared with metformin alone (a) to reduce cIMT and progression of carotid plaque height by 0.01 mm/year, using a mean difference between groups of 0.01 mm/year with SD 0.02 (or the fish oil intervention group will have a 75% mean reduction compared with the control group), and (b) to reduce LV-GLS by 0.01%/year using a mean difference between groups of 0.01%/year with SD 0.015. These estimates fall within our sample size estimate of n=73 for each treatment arm. To adjust for the multiple primary outcomes, we will include Bonferroni and Hochberg corrections as adequate to prevent inflated false positive results in the analysis. We define a clinically meaningful difference as a 20% reduction in progression of cIMT, carotid plaque height or LV-GLS. Sample size calculations were completed using Power Analysis and Sample Size statistical software (PASS 2008, NCSS). Statistical analysis Patient demographic and characteristic variables will be summarised by mean and SD for normally distributed variables and by median and quartiles for non-normally distributed continuous data. Categorical data will be presented as absolute and relative frequencies (n and %). Χ2 tests will be used to compare categorical baseline variables such as age, obesity, known comorbidities and treatment variables (fish oil vs placebo). CIs will be provided as required. Outcome variables derived from biochemical and cardiovascular analysis will be compared as changes over time from start to end of the intervention between and within the two treatment groups using analysis of variance (ANOVA)/repeated measures ANOVA as applicable. Treatment efficacy will be evaluated by comparing the slope of the progression lines of cIMT and carotid plaque height/time in both treatment groups. Standard intention-to-treat analysis for clinical trials will be used and this maximises the pragmatic translation of findings to clinical practice.92 We will fit linear regression models to examine the relationship between the primary outcome variables of progression of cIMT (mm/year) and progression of carotid plaque height (mm/year), PWV and cardiac morphology-function indices with secondary outcome variables of fasting and non-fasting plasma TG and apoB-lipoproteins, hormones and cardiometabolic risk factors. The Akaike Information Criterion (AIC) statistics will be used to assess overall model fit. Analysis of covariance with false discovery rate correction for multiple comparisons will be used to test for group differences in all continuous variables collected from the MRI. Statistical analysis will be performed using IBM SPSS Statistics (V.28.0); statistical significance will be defined as p<0.05. Validated questionnaires (PCOSQOL, PROMIS-29) will be analysed according to their respective guidelines.113–115 Where applicable, ratings from clinic visit 1 and visit 5 will be compared using Student’s t-tests. Qualitative analysis will be applied to participant interviews. Missing and spurious data Observed data from all randomised participants will be included in the analysis. If the number of missing data is between 5% and 30%, we will use the imputation method. To avoid spurious correlation, we will ensure an adequate sample size and control for external variables such as age and BMI in subgroup analysis. To meet trial standards and improve transparency and completeness of outcome reporting, the results of the trial will be reported according to Consolidated Standards of Reporting Trials (CONSORT) guidelines.117 The statistical analysis plan is accessible together with the study protocol after publication acceptance. Patient and public involvement Our PMOS researchers collaborate with a dedicated group of PMOS patient partners. For this randomised clinical trial, patient partners were involved in providing feedback on the study design, especially on issues regarding study feasibility and mitigating challenges. Patient partners involved in our pilot study provided lived experience and feedback to incorporate into the study design, protocol and intervention.36 We will engage our patient partners to actively participate in recruitment through PMOS-related social networks and to provide feedback on the interpretation of new findings to increase the translation and relevance of study outcomes to this population. The inclusion of a patient partner (SC) as an author acknowledges their contribution to study design and protocol, as well as expected involvement in recruitment, data interpretation and dissemination of outcomes through PMOS social media groups. This will provide a lived experience perspective to the study findings and will ensure dissemination of knowledge in plain language that is clear to the wider PMOS community. Ethics and dissemination Ethics approval and consent The trial will be conducted in compliance with the protocol approved by the University of Alberta Health Research Ethics Board (Pro00141704), in accordance with the ethical principles originating from the Declaration of Helsinki, Good Clinical Practice (GCP) guidelines and applicable regulatory requirements. A No Objection Letter was issued from Health Canada for this trial. The consent process will be initiated at the time of enrolment into the study and will continue throughout study participation. Participants meeting the eligibility criteria for the study will have the study explained to them by one member of the study team by phone. If the participant is willing to consent to study participation, they will receive a link to their REDCap file to provide consent in the form of an e-signature. The consent will include all data collected as part of the trial, including the verification of PMOS and medical conditions from healthcare records and data from surveys (demographic, medical history, QOL) completed by the participants via a REDCap survey link. An example of the participant consent form is included in online supplemental file 1. Withdrawal Participants have a right to withdraw from the study for any reason at any time. They may notify the clinical coordinator or registered dietitian, who monitors compliance. The research team has the right to withdraw participants from the study if (1) the participant becomes pregnant, (2) the participant requires or starts to use a non-permitted concomitant medication and (3) a change in the participant’s health status occurs which, in the opinion of the investigators, would compromise the data collected. Participants can opt out of specific tests for health reasons and in consultation with the study physician. Confidentiality Confidentiality of trial participants is strictly held in trust by the participating investigators, their staff and sponsors. This confidentiality includes clinical information, laboratory tests and surveys. Participant data will be deposited and maintained in a secure REDCap database hosted at the WCHRI at the University of Alberta in Edmonton, Canada, and accessible only to the research team.93 For analysis, data will be deidentified and will contain only a unique study ID number. Oversight and monitoring Data will be generated, documented and recorded in compliance with the study protocol, Health Canada regulations, standard operating procedures and institutional policies. We will keep a regulatory binder in the form of electronic records in a separate REDCap database to contain all essential documents supporting the validity, quality and integrity of the data produced in the trial. All deviations from the original protocol will be recorded. Trial initiation, annual interim monitoring and study close-out will be performed by the Clinical Trials Office (CTO) group within the University of Alberta to ensure adherence to the protocol, compliance with GCP and regulatory guidelines, completeness, consistency and accuracy of the data being recorded, and that informed consents are obtained and recorded for all trial participants. The CTO will conduct interim auditing in collaboration with study investigators and assist with decisions to amend the trial protocol. Known and potential risks We do not anticipate unexpected health issues that would necessitate a discontinuation of the trial as fish oil is considered generally safe alone and in combination with metformin at the dosage proposed.36 Minor side effects can include digestive symptoms such as gastric reflux, diarrhoea and nausea.96 All testing will be provided by trained technicians. For blood testing, a trained phlebotomist will be used to minimise risk of mental or physical discomfort. Participants are screened for MRI safety and will have access to buttons to push in scanners to alert technicians of feelings of unwell or claustrophobia during tests. All unexpected adverse events and follow-up evaluations will be recorded as required by regulatory protocols. Interim analysis will be conducted by the research team including the study principal investigator (PI) and QI and discussed in group meetings. The final decision to terminate the trial rests with the PI and QI. Dissemination of results The investigators and sponsors are planning to communicate trial outcomes to the wider public, including trial participants, the PMOS community and healthcare professionals who manage patients with PMOS. The results of this trial will be uploaded to ClinicalTrials.gov and to our PMOS Together website. Furthermore, the authors plan to develop infographics of the results to present the findings at community forums, on social media and scientific meetings and conferences, and will publish manuscripts from this trial in peer-reviewed scientific journals. Trial status Protocol version 13 August 2025. Recruitment was initiated in November 2025, and the trial is scheduled to be completed in July 2028. Discussion A safe, well-tolerated and effective intervention that targets pre-diabetes risk, atherogenic dyslipidaemia, premature ACVD and cardiac remodelling-dysfunction is needed to reduce premature CVD in high-risk young women with elevated body weight and PMOS.9 42 This protocol outlines the first randomised, placebo-controlled trial designed to generate new knowledge on the effect of fish oil and metformin on plasma TG and apoB-lipoproteins, and on progression of atherosclerosis, endothelial dysfunction and cardiac remodelling-dysfunction in young high-risk women with PMOS. Metformin is the standard of care to manage pre-diabetes and improve insulin sensitivity in patients with PMOS; however, it does not necessarily improve dyslipidaemia in this high-risk population.48 49 51 52 There is ample evidence from randomised clinical trials and meta-analyses that EPA-containing and DHA-containing fish oil can decrease fasting and non-fasting TG and total apoB-lipoproteins in the metabolic syndrome and in patients with PMOS.36 64–69 72 Reductions in TG and apoB-lipoprotein remnant-C are associated with a significant reduction in clinical CVD risk and ischaemic events.34 36 70–75 77 118 Yet, no study to date has investigated the combination of fish oil with metformin on apoB-lipoproteins and the effect on ACVD, endothelial dysfunction and cardiac remodelling-dysfunction.64 66–68 72 119–122 Fish oil and metformin may have synergistic effects to improve vascular and endothelial function.123 We hypothesise that the combination of metformin to improve pre-diabetic risk and fish oil to lower TG and apoB-lipoproteins will improve atherogenic dyslipidaemia and reduce the progression of ACVD, including cIMT and carotid plaque, endothelial dysfunction and cardiac remodelling-dysfunction in high-risk young women with PMOS. Our proposed study is a 12-month randomised, placebo-controlled trial designed to test this hypothesis. If the results show fish oil is effective in limiting progression of subclinical CVD in combination with metformin therapy, and we can demonstrate that this is associated with reduced atherogenic dyslipidaemia, then these results will provide evidence to support the potential use of fish oil in clinical practice to reduce premature CVD risk in women with PMOS.64 122 124 The study will also provide evidence-based research on the potential use of screening and monitoring of ACVD and cardiac remodelling-dysfunction in high-risk young women with PMOS. Study strengths The design for this trial is double blinded, parallel and placebo controlled, allowing for a rigorous and thorough investigation of the effect of fish oil on the target population. An advantage is the combination of two established compounds: metformin is a well-characterised and well-tolerated standard-of-care medication for women with obesity and PMOS to manage insulin resistance and pre-diabetes49 52 87; fish oil is a well-established, safe and inexpensive dietary supplement to lower plasma TG and apoB-48 lipoproteins and can be conveniently added as an adjunct therapy to metformin.36 56 122 In addition, fish oil supplementation can be easily mimicked with the olive oil placebo. We are testing fish oil in combination with metformin in those individuals who may already be using metformin, so they do not have to withdraw from using this standard-of-care treatment. The design of this trial also includes diet and lifestyle counselling at regular intervals, which is an integral first-line recommendation in patients with PMOS.87 Furthermore, the trial aims to explore participant QOL and satisfaction, acceptability and feasibility of the intervention to help translate to clinical practice implementation and inform potential larger scale multicentre trials in the future. Study limitations and mitigation strategies Studies lasting for a significant amount of time, such as our 12-month study, are prone to participant dropout. To account for this, we have included a 15% dropout rate in power-sample size calculations. From our clinical experience, individuals with PMOS are eager to participate in PMOS-related research, in particular research interventions that aim to lower their risk of comorbidities including diabetes and CVD.32 36 98 99 125 Adherence to the different aspects of the intervention, fish oil, metformin and recording 24-hour food intake may be cumbersome for some individuals. To mitigate potential dropout and increase adherence, our PMOS research team will communicate regularly with our participants on a monthly or as needed basis to review and encourage their adherence and participation in the trial. In the current trial, we are limiting our participants to high-risk individuals with PMOS, which include those with overweight-obesity, metabolic syndrome and/or T2D, as they are at greater risk of subclinical ACVD, endothelial dysfunction and cardiac remodelling-dysfunction.32 This may restrict the generalisability of the outcomes to other women, including females without PMOS who are overweight-obese and present with metabolic syndrome and T2D, as well as healthy-weight individuals with PMOS who may have elevated insulin and blood lipids. Young high-risk women of reproductive age have limited safe and effective therapeutic options to target elevated blood lipids, premature ACVD and cardiac remodelling-dysfunction; therefore, this trial can provide proof of principle for the opportunity to modify risk factors and prevention of disease progression.88 89 126 If fish oil as an adjunct therapy to standard-of-care metformin is found to be effective in reducing atherogenic dyslipidaemia and progression of ACVD, these findings may inform the design of future studies in other high-risk female populations, such as those with a family history of CVD, those undergoing assisted fertility treatment, women at risk of cardiovascular pregnancy complications and those with increased menopausal CVD risk.22 25 31 53 88 89 126–128 The use of various medications, including anti-androgens, other diabetes medications and hormonal contraception, by our patient population may be regarded as confounding factors; however, inclusion of these medications allows for a pragmatic trial in terms of translating the findings to reflect typical clinical practice and real patient lived experience, and we plan to factor the use of these medications into post hoc statistical analyses.36 The proposed 12-month intervention may not be long enough to assess a reduction in progression of ACVD, endothelial dysfunction and cardiac remodelling-dysfunction; however, it will provide us with data to inform the design of future studies. Our previous study demonstrated fish oil reduces plasma TG and apoB48-cholesterol remnant levels after 3 months, and these biomarkers are causative in atherogenesis.36 74 Therefore, we anticipate fish oil will prevent progression of these indices over a 12-month period. In addition, fish oil supplementation in a young high-risk population may have greater effectiveness in preventing the progression of ACVD, endothelial dysfunction and cardiac remodelling-dysfunction compared with studies in older adults.101 102 Supplementary material The funding body has no role in the design of the study; in the collection, analysis and interpretation of data; and in writing the manuscript. Footnotes Funding: Funding is provided by the Heart and Stroke Foundation of Canada (grant number G-23-0033990) and by the Alberta Women’s Health Foundation through the Women and Children’s Health Research Institute (WCHRI) at the University of Alberta. Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-124025). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details. References Supplementary Materials